Story perspectives

Metformin May Cut Macular Degeneration Risk by 37%

2/6/2026

44 10

Summary

Story summary

A study suggests metformin may reduce progression to intermediate macular degeneration by 37%.
The study tracked over 2,000 individuals with diabetes using detailed eye photographs, offering a more accurate assessment.
Laboratory studies show metformin's anti-inflammatory effects and its ability to clear cellular damage, but benefits are unconfirmed in AMD.
Researchers call for a randomized trial to test metformin.
They advise those not taking metformin to consult clinicians before changing medications.

1 of 1

Story summary

A study suggests metformin may reduce progression to intermediate macular degeneration by 37%.
The study tracked over 2,000 individuals with diabetes using detailed eye photographs, offering a more accurate assessment.
Laboratory studies show metformin's anti-inflammatory effects and its ability to clear cellular damage, but benefits are unconfirmed in AMD.
Researchers call for a randomized trial to test metformin.
They advise those not taking metformin to consult clinicians before changing medications.